Chondrogianni N, Trougakos IP, Kletsas D, Chen QM, Gonos ES Partial proteasome inhibition in human fibroblasts triggers accelerated M1 senescence or M2 crisis depending on p53 and Rb status. Aging Cell. 2008 Oct;7(5):717-32. doi: 10.1111/j.1474-9726.2008.00425.x. Epub 2008 Aug 1.
Morimoto RI, Cuervo AM Proteostasis and the aging proteome in health and disease. J Gerontol A Biol Sci Med Sci. 2014 Jun;69 Suppl 1:S33-8. doi: 10.1093/gerona/glu049. Review.
Palombella VJ, Rando OJ, Goldberg AL, Maniatis T The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. Cell. 1994 Sep 9;78(5):773-85.
Patterson C, Cyr D Welcome to the machine: a cardiologist's introduction to protein folding and degradation. Circulation. 2002 Nov 19;106(21):2741-6. Review.
Safar ME, Levy BI, Struijker-Boudier H Current perspectives on arterial stiffness and pulse pressure in hypertension and cardiovascular diseases. Circulation. 2003 Jun 10;107(22):2864-9. Review.
Trougakos IP, Sesti F, Tsakiri E, Gorgoulis VG Non-enzymatic post-translational protein modifications and proteostasis network deregulation in carcinogenesis. J Proteomics. 2013 Oct 30;92:274-98. doi: 10.1016/j.jprot.2013.02.024. Epub 2013 Mar 14. Review.
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.
